Q3 EPS Estimates for Sanara MedTech Raised by HC Wainwright

Key Points

• HC Wainwright has increased its Q3 2025 EPS estimate for Sanara MedTech from ($0.32) to ($0.24), maintaining a "Buy" rating with a target price of $54.00.
• Sanara MedTech's latest earnings report showed a loss of ($0.23) per share, which was better than the consensus estimate of ($0.33), suggesting a positive trend in performance.
• The company has attracted interest from institutional investors, with JPMorgan Chase increasing its holdings by 234.5% in the last quarter.

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Stock analysts at HC Wainwright boosted their Q3 2025 EPS estimates for shares of Sanara MedTech in a research report issued on Monday, August 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.24) per share for the quarter, up from their previous estimate of ($0.32). HC Wainwright currently has a "Buy" rating and a $54.00 price objective on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech's Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($1.08) EPS and FY2026 earnings at ($0.84) EPS.

Sanara MedTech Trading Up 11.2%

NASDAQ:SMTI traded up $3.43 during trading hours on Wednesday, hitting $33.95. The stock had a trading volume of 93,685 shares, compared to its average volume of 44,310. Sanara MedTech has a one year low of $23.53 and a one year high of $39.08. The company has a debt-to-equity ratio of 1.25, a quick ratio of 2.03 and a current ratio of 2.26. The company has a market cap of $302.16 million, a price-to-earnings ratio of -29.27 and a beta of 1.26. The business's 50 day moving average is $27.92 and its 200-day moving average is $30.34.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.10. The firm had revenue of $25.83 million for the quarter, compared to analyst estimates of $25.15 million. Sanara MedTech had a negative return on equity of 26.43% and a negative net margin of 10.22%.

Institutional Trading of Sanara MedTech

Hedge funds have recently added to or reduced their stakes in the business. Lazard Asset Management LLC raised its position in Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company's stock worth $89,000 after acquiring an additional 3,155 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Sanara MedTech by 144.3% during the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company's stock worth $2,030,000 after purchasing an additional 42,237 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Sanara MedTech in the 2nd quarter valued at about $382,000. Stephens Inc. AR lifted its stake in Sanara MedTech by 18.0% in the 2nd quarter. Stephens Inc. AR now owns 12,794 shares of the company's stock valued at $363,000 after purchasing an additional 1,952 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in Sanara MedTech by 14.9% in the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company's stock valued at $115,000 after purchasing an additional 483 shares during the last quarter. Institutional investors and hedge funds own 8.10% of the company's stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.